Author:
Molaei Emad,Molaei Ali,Hayes A. Wallace,Karimi Gholamreza
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. (2022) Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. The Lancet 399: 1941–1953
2. Abedi F, Rezaee R, Karimi G (2020) Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19). Pharmacol Res 156:104808
3. Abedi F, Rezaee R, Hayes AW, Nasiripour S, Karimi G (2021) MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? Cell Cycle 20:143–153
4. Ackley TW, McManus D, Topal JE, Cicali B, Shah S (2021) A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother 65:e02290–20
5. (ACOG) ACoOaG (2022) COVID-19 FAQs for obstetricians-gynecologists,obstetrics., https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献